Health
Experimental intranasal influenza vaccine produces durable immune response – News-Medical.Net
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal…
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells.
The investigational vaccine was developed by Emergent Biosolutions Inc., (Gaithersburg,…
-
Noosa News23 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush
-
Business23 hours agoWhy this investing expert is calling time on NAB shares
-
General19 hours agoFederal government funding extends cohealth GP services until July 2026
-
Noosa News17 hours agoSunshine Coast Airport receives green light for major upgrade opening doors to growth jobs and tourism across the region